2.9950
+0.0250
+(0.84%)
As of 12:45:21 PM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
235
235
353
10,386
--
Operating Expense
68,149
68,149
55,272
56,790
34,015
Operating Income
-67,914
-67,914
-54,919
-46,404
-34,015
Other Income Expense
3,892
3,892
4,522
1,061
238
Pretax Income
-64,022
-64,022
-50,397
-45,343
-33,777
Net Income Common Stockholders
-64,023
-64,023
-50,389
-45,338
-33,768
Diluted NI Available to Com Stockholders
-64,023
-64,023
-50,389
-45,338
-33,768
Basic EPS
-0.86
-0.86
-0.94
-1.60
-1.77
Diluted EPS
-0.86
-0.86
-0.94
-1.60
-1.77
Basic Average Shares
74,261.2650
74,261.2650
53,606.4880
28,419.5690
19,080.8780
Diluted Average Shares
74,261.2650
74,261.2650
53,606.4880
28,419.5690
19,080.8780
Total Operating Income as Reported
-67,914
-67,914
-54,919
-46,404
-34,015
Total Expenses
68,149
68,149
55,272
56,790
34,015
Net Income from Continuing & Discontinued Operation
-64,023
-64,023
-50,389
-45,338
-33,768
Normalized Income
-64,023
-64,023
-50,389
-45,338
-33,768
EBIT
-67,914
-67,914
-54,919
-46,404
-34,015
EBITDA
-66,374
-66,374
-52,178
-44,709
-32,711
Reconciled Depreciation
1,540
1,540
2,741
1,695
1,304
Net Income from Continuing Operation Net Minority Interest
-64,023
-64,023
-50,389
-45,338
-33,768
Normalized EBITDA
-66,374
-66,374
-52,178
-44,709
-32,711
12/31/2021 - 5/7/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NKTR Nektar Therapeutics
0.6017
-2.59%
LXEO Lexeo Therapeutics, Inc.
2.0050
+1.26%
LRMR Larimar Therapeutics, Inc.
1.8500
+2.22%
RCKT Rocket Pharmaceuticals, Inc.
5.63
+6.74%
RZLT Rezolute, Inc.
2.5300
+2.44%
SRRK Scholar Rock Holding Corporation
28.78
+2.79%
CMPX Compass Therapeutics, Inc.
1.6450
-2.95%
CMMB Chemomab Therapeutics Ltd.
1.1404
+5.59%
MGTX MeiraGTx Holdings plc
5.36
+3.08%
MIST Milestone Pharmaceuticals Inc.
0.8116
+5.22%